(Q90557208)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

title

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

1 reference

Gustavo Luna

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Peter Alping

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Joachim Burman

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Katharina Fink

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Anna Fogdell-Hahn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Martin Gunnarsson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Jan Hillert

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Annette Langer-Gould

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Jan Lycke

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Petra Nilsson

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Jonatan Salzer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Anders Svenningsson

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Magnus Vrethem

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Tomas Olsson

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Fredrik Piehl

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

Thomas Frisell

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

publication date

7 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

14 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31589278%20AND%20SRC:MED&resulttype=core&format=json

The new Swedish Prescribed Drug Register--opportunities for pharmacoepidemiological research and experience from the first six months

14 April 2020

cites work

1 reference

12 December 2020

Imputing missing covariate values for the Cox model

1 reference

12 December 2020

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

1 reference

12 December 2020

External review and validation of the Swedish national inpatient register

1 reference

12 December 2020

Hospital admission due to infections in multiple sclerosis patients

1 reference

12 December 2020

Established and novel disease-modifying treatments in multiple sclerosis

1 reference

12 December 2020

A changing treatment landscape for multiple sclerosis: challenges and opportunities

1 reference

12 December 2020

Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program

1 reference

12 December 2020

Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management

1 reference

12 December 2020

Rituximab treatment did not aggravate ongoing progressive multifocal leukoencephalopathy in a patient with multiple sclerosis

1 reference

12 December 2020

The Swedish MS registry – clinical support tool and scientific resource

1 reference

12 December 2020

Disease-modifying therapies and infectious risks in multiple sclerosis

1 reference

12 December 2020

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy

1 reference

12 December 2020

Safety concerns and risk management of multiple sclerosis therapies

1 reference

12 December 2020

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

1 reference

12 December 2020

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

1 reference

12 December 2020

Infections in Patients Receiving Multiple Sclerosis Disease-Modifying Therapies.

1 reference

12 December 2020

Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

1 reference

12 December 2020

Disease-modifying drugs for multiple sclerosis and infection risk: a cohort study.

1 reference

12 December 2020

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

1 reference

12 December 2020

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations

1 reference

12 December 2020